GI Oncology Now Conference Coverage
GI Oncology Now reviews education from ASCO GI 2024, featuring the latest advances in the field of GI cancer research.
Coverage of the 2024 ASCO GI Symposium, focusing on liver cancer
GI Oncology Now reviews education from ISGIO 2023, featuring the latest advances in the field of GI cancer research.
GI Oncology Now reviews practice-enhancing education from CIO 2023, featuring multidisciplinary specialties in oncology.
Advertisement
The Latest From GI Oncology Now
Dr. Pant describes the improved DOR and median OS seen with the treatment, and discusses the ongoing phase 3 trial.
The approval is based on positive results of the CodeBreaK300 trial, which demonstrated an improvement in PFS.
Dr. Cytryn reviews the FDA approval of tislelizumab and shares thoughts on its clinical impact.
The peripheral blood transcriptome of NET patients showed differential enrichment of 30 systemic cancer hallmarks.
Drs. Finn and Yopp discuss adjuvant therapy in HCC following surgical resection in a review of data from IMbrave050.
Adding a taxane to the standard regimen of gemcitabine/cisplatin does not improve OS in patients with newly diagnosed BTC.
Drs. Finn and Yopp discuss the IMbrave050 study for early-stage HCC, including the trial design, results, and implications.
A recent study reviewed global disparities in gastric cancer screening, finding limited research about screening feasibility.
Advertisement
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.